You are here

  • Home
  • Archive
  • Volume 105, Issue 3
  • Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study

Article metrics

Article menu

Download PDFPDF

Clinical science
Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study

 

Online download statistics by month:

Online download statistics by month: May 2020 to March 2024

AbstractFullPdf
May 2020462461275
Jun 2020183618211510
Jul 202010531049707
Aug 202013212756
Sep 202012712423
Oct 2020979722
Nov 2020999915
Dec 20201099816
Jan 202110510129
Feb 202126426244
Mar 202123522947
Apr 2021928840
May 2021585617
Jun 2021746915
Jul 2021777824
Aug 2021636226
Sep 2021777613
Oct 2021867940
Nov 2021646422
Dec 2021555526
Jan 2022868718
Feb 2022696920
Mar 202213413228
Apr 202211811723
May 202213713619
Jun 202219419129
Jul 202254569
Aug 2022767622
Sep 2022636320
Oct 2022494811
Nov 2022757312
Dec 202229298
Jan 2023393811
Feb 202348497
Mar 2023383912
Apr 2023525920
May 202319189
Jun 2023535114
Jul 2023262613
Aug 2023333118
Sep 202326259
Oct 2023353313
Nov 2023312614
Dec 202349417
Jan 2024201915
Feb 2024282811
Mar 2024383524
Total678466903383